2′–5′ Oligoadenylate synthetase-like 1 (OASL1) deficiency in mice promotes an effective anti-tumor immune response by enhancing the production of type I interferons

Chan Kyu Sim, Yeon Sook Cho, Byung Soo Kim, In Jeoung Baek, Young-Joon Kim, Myeong Sup Lee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Type I interferon (IFN-I) plays a critical role in antiviral and antitumor defense. In our previous studies, we showed that IFN-I-inducible 2′–5′ oligoadenylate synthetase-like 1 (OASL1) negatively regulates IFN-I production upon viral infection by specifically inhibiting translation of the IFN-I-regulating master transcription factor, interferon regulatory factor 7 (IRF7). In this study, we investigated whether OASL1 plays a negative role in the anti-tumor immune response by using OASL1-deficient (Oasl1−/−) mice and transplantable syngeneic tumor cell models. We found that Oasl1−/− mice demonstrate enhanced resistance to lung metastatic tumors and subcutaneously implanted tumors compared to wild-type (WT) mice. Additionally, we found that cytotoxic effector cells such as CD8+ T cells (including tumor antigen-specific CD8+ T cells) and NK cells as well as CD8α+ DCs (the major antigen cross-presenting cells) were much more frequent (>fivefold) in the Oasl1−/− mouse tumors. Furthermore, the cytotoxic effector cells in Oasl1−/− mouse tumors seemed to be more functionally active. However, the proportion of immunosuppressive myeloid-derived suppressor cells within hematopoietic cells and of regulatory T cells within CD4+ T cells in Oasl1−/− mouse tumors did not differ significantly from that of WT mice. Tumor-challenged Oasl1−/− mice expressed increased levels of IFN-I and IRF7 protein in the growing tumor, indicating that the enhanced antitumor immune response observed in Oasl1−/− mice was caused by higher IFN-I production in Oasl1−/− mice. Collectively, these results show that OASL1 deficiency promotes the antitumor immune response, and thus, OASL1 could be a good therapeutic target for treating tumors.

Original languageEnglish
Pages (from-to)663-675
Number of pages13
JournalCancer Immunology, Immunotherapy
Volume65
Issue number6
DOIs
Publication statusPublished - 2016 Jun 1

Fingerprint

Interferon Type I
Ligases
Neoplasms
Interferon Regulatory Factor-7
T-Lymphocytes
2',5'-oligoadenylate
Neoplasm Antigens
Antigen-Presenting Cells
Virus Diseases
Regulatory T-Lymphocytes
Immunosuppressive Agents
Natural Killer Cells
Antiviral Agents
Transcription Factors
Lung

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

@article{117b8715340343ef860367e0b17e1d40,
title = "2′–5′ Oligoadenylate synthetase-like 1 (OASL1) deficiency in mice promotes an effective anti-tumor immune response by enhancing the production of type I interferons",
abstract = "Type I interferon (IFN-I) plays a critical role in antiviral and antitumor defense. In our previous studies, we showed that IFN-I-inducible 2′–5′ oligoadenylate synthetase-like 1 (OASL1) negatively regulates IFN-I production upon viral infection by specifically inhibiting translation of the IFN-I-regulating master transcription factor, interferon regulatory factor 7 (IRF7). In this study, we investigated whether OASL1 plays a negative role in the anti-tumor immune response by using OASL1-deficient (Oasl1−/−) mice and transplantable syngeneic tumor cell models. We found that Oasl1−/− mice demonstrate enhanced resistance to lung metastatic tumors and subcutaneously implanted tumors compared to wild-type (WT) mice. Additionally, we found that cytotoxic effector cells such as CD8+ T cells (including tumor antigen-specific CD8+ T cells) and NK cells as well as CD8α+ DCs (the major antigen cross-presenting cells) were much more frequent (>fivefold) in the Oasl1−/− mouse tumors. Furthermore, the cytotoxic effector cells in Oasl1−/− mouse tumors seemed to be more functionally active. However, the proportion of immunosuppressive myeloid-derived suppressor cells within hematopoietic cells and of regulatory T cells within CD4+ T cells in Oasl1−/− mouse tumors did not differ significantly from that of WT mice. Tumor-challenged Oasl1−/− mice expressed increased levels of IFN-I and IRF7 protein in the growing tumor, indicating that the enhanced antitumor immune response observed in Oasl1−/− mice was caused by higher IFN-I production in Oasl1−/− mice. Collectively, these results show that OASL1 deficiency promotes the antitumor immune response, and thus, OASL1 could be a good therapeutic target for treating tumors.",
author = "Sim, {Chan Kyu} and Cho, {Yeon Sook} and Kim, {Byung Soo} and Baek, {In Jeoung} and Young-Joon Kim and Lee, {Myeong Sup}",
year = "2016",
month = "6",
day = "1",
doi = "10.1007/s00262-016-1830-9",
language = "English",
volume = "65",
pages = "663--675",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "6",

}

2′–5′ Oligoadenylate synthetase-like 1 (OASL1) deficiency in mice promotes an effective anti-tumor immune response by enhancing the production of type I interferons. / Sim, Chan Kyu; Cho, Yeon Sook; Kim, Byung Soo; Baek, In Jeoung; Kim, Young-Joon; Lee, Myeong Sup.

In: Cancer Immunology, Immunotherapy, Vol. 65, No. 6, 01.06.2016, p. 663-675.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 2′–5′ Oligoadenylate synthetase-like 1 (OASL1) deficiency in mice promotes an effective anti-tumor immune response by enhancing the production of type I interferons

AU - Sim, Chan Kyu

AU - Cho, Yeon Sook

AU - Kim, Byung Soo

AU - Baek, In Jeoung

AU - Kim, Young-Joon

AU - Lee, Myeong Sup

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Type I interferon (IFN-I) plays a critical role in antiviral and antitumor defense. In our previous studies, we showed that IFN-I-inducible 2′–5′ oligoadenylate synthetase-like 1 (OASL1) negatively regulates IFN-I production upon viral infection by specifically inhibiting translation of the IFN-I-regulating master transcription factor, interferon regulatory factor 7 (IRF7). In this study, we investigated whether OASL1 plays a negative role in the anti-tumor immune response by using OASL1-deficient (Oasl1−/−) mice and transplantable syngeneic tumor cell models. We found that Oasl1−/− mice demonstrate enhanced resistance to lung metastatic tumors and subcutaneously implanted tumors compared to wild-type (WT) mice. Additionally, we found that cytotoxic effector cells such as CD8+ T cells (including tumor antigen-specific CD8+ T cells) and NK cells as well as CD8α+ DCs (the major antigen cross-presenting cells) were much more frequent (>fivefold) in the Oasl1−/− mouse tumors. Furthermore, the cytotoxic effector cells in Oasl1−/− mouse tumors seemed to be more functionally active. However, the proportion of immunosuppressive myeloid-derived suppressor cells within hematopoietic cells and of regulatory T cells within CD4+ T cells in Oasl1−/− mouse tumors did not differ significantly from that of WT mice. Tumor-challenged Oasl1−/− mice expressed increased levels of IFN-I and IRF7 protein in the growing tumor, indicating that the enhanced antitumor immune response observed in Oasl1−/− mice was caused by higher IFN-I production in Oasl1−/− mice. Collectively, these results show that OASL1 deficiency promotes the antitumor immune response, and thus, OASL1 could be a good therapeutic target for treating tumors.

AB - Type I interferon (IFN-I) plays a critical role in antiviral and antitumor defense. In our previous studies, we showed that IFN-I-inducible 2′–5′ oligoadenylate synthetase-like 1 (OASL1) negatively regulates IFN-I production upon viral infection by specifically inhibiting translation of the IFN-I-regulating master transcription factor, interferon regulatory factor 7 (IRF7). In this study, we investigated whether OASL1 plays a negative role in the anti-tumor immune response by using OASL1-deficient (Oasl1−/−) mice and transplantable syngeneic tumor cell models. We found that Oasl1−/− mice demonstrate enhanced resistance to lung metastatic tumors and subcutaneously implanted tumors compared to wild-type (WT) mice. Additionally, we found that cytotoxic effector cells such as CD8+ T cells (including tumor antigen-specific CD8+ T cells) and NK cells as well as CD8α+ DCs (the major antigen cross-presenting cells) were much more frequent (>fivefold) in the Oasl1−/− mouse tumors. Furthermore, the cytotoxic effector cells in Oasl1−/− mouse tumors seemed to be more functionally active. However, the proportion of immunosuppressive myeloid-derived suppressor cells within hematopoietic cells and of regulatory T cells within CD4+ T cells in Oasl1−/− mouse tumors did not differ significantly from that of WT mice. Tumor-challenged Oasl1−/− mice expressed increased levels of IFN-I and IRF7 protein in the growing tumor, indicating that the enhanced antitumor immune response observed in Oasl1−/− mice was caused by higher IFN-I production in Oasl1−/− mice. Collectively, these results show that OASL1 deficiency promotes the antitumor immune response, and thus, OASL1 could be a good therapeutic target for treating tumors.

UR - http://www.scopus.com/inward/record.url?scp=84962147273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962147273&partnerID=8YFLogxK

U2 - 10.1007/s00262-016-1830-9

DO - 10.1007/s00262-016-1830-9

M3 - Article

VL - 65

SP - 663

EP - 675

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 6

ER -